WHO Model Prescribing Information: Drugs Used in Skin Diseases
(1997; 132 pages) [French] [Spanish] Voir le document au format PDF
Table des matières
Afficher le documentPreface
Afficher le documentIntroduction
Ouvrir ce répertoire et afficher son contenuParasitic infections
Ouvrir ce répertoire et afficher son contenuInsect and arachnid bites and stings
Ouvrir ce répertoire et afficher son contenuSuperficial fungal infections
Ouvrir ce répertoire et afficher son contenuSubcutaneous fungal infections
Ouvrir ce répertoire et afficher son contenuBacterial infections
Ouvrir ce répertoire et afficher son contenuViral infections
Ouvrir ce répertoire et afficher son contenuEczematous diseases
Ouvrir ce répertoire et afficher son contenuScaling diseases
Ouvrir ce répertoire et afficher son contenuPapulosquamous diseases
Afficher le documentCutaneous reactions to drugs
Ouvrir ce répertoire et afficher son contenuPigmentary disorders
Fermer ce répertoirePremalignant lesions and malignant tumours
Afficher le documentActinic keratosis
Afficher le documentBasal cell and squamous cell carcinomas
Afficher le documentMalignant melanoma
Ouvrir ce répertoire et afficher son contenuPhotodermatoses
Ouvrir ce répertoire et afficher son contenuBullous dermatoses
Afficher le documentAlopecia areata
Afficher le documentUrticaria
Ouvrir ce répertoire et afficher son contenuConditions common in children
Afficher le documentAcne vulgaris
Afficher le documentPruritus
Afficher le documentTropical ulcers
Ouvrir ce répertoire et afficher son contenuAntimicrobial drugs
Ouvrir ce répertoire et afficher son contenuAntifugal drugs
Ouvrir ce répertoire et afficher son contenuAntiseptic agents
Ouvrir ce répertoire et afficher son contenuKeratoplastic and keratolytic agents
Ouvrir ce répertoire et afficher son contenuScabicides and pediculicides
Ouvrir ce répertoire et afficher son contenuAnti-inflammatory and antipruritic drugs1
Ouvrir ce répertoire et afficher son contenuAntiallergics and drugs used in anaphylaxis
Ouvrir ce répertoire et afficher son contenuUltraviolet radiation-blocking agents (sunscreens)
Ouvrir ce répertoire et afficher son contenuMiscellaneous drugs
Ouvrir ce répertoire et afficher son contenuAnnex
Afficher le documentSelected WHO Publications of Related Interest
Afficher le documentBack cover
 

Malignant melanoma

Malignant melanoma resulting from malignant changes in cutaneous melanocytes is the most fatal form of skin cancer. None the less, with proper early diagnosis and adequate excision of the lesions, most melanomas can be treated without long-term consequences. Most melanomas develop from the normal melanocyte population of the skin, but 30-40% may arise from pre-existing moles. Signs that malignant changes may be occurring (although not predictive in themselves) include a rapid change in size, a change in colour (with or without spread of pigment to the adjacent skin), inflammation of the surrounding skin, and bleeding or ulceration of a pigmented lesion. Early lesions may be flat and look like an unusual freckle. The colour is not uniform with areas of dark coloration contrasting with light areas. This variation in colour is a particularly important sign.

Treatment

Suspicious lesions that are small in size (e.g. diameter ≤ 6 mm) should be excised with a border of 3-4 mm initially. If the lesions are too large to excise, biopsies should be taken for histological examination. The depth of the lesion should be determined, if possible, as this is important in deciding whether additional surgery is required and is also essential for prognosis. Re-excision of margins of normal skin between 1 and 2 cm in width around the original tumour may be done, depending on the depth of invasion found on histological examination. The depth of invasion in the skin is also an important factor in determining the potential for the lesion to metastasize to distant sites.

 

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 24 avril 2012